Abstract: It is fundamental to activate systemic immune response for long-term anti-tumor efficacy in vivo. Radiotherapy and chemotherapy can not only induce apoptosis, but also immunogenic cell death (ICD) of tumor cells. Once tumor cells undergo ICD, dying cells release damage-related molecular patterns (DAMPs), which then recruit antigen-presenting cells to engulf and process tumor cell antigens, and further activate adaptive immune response. Therefore, the application of ICD inducers in tumor therapy is of great significance for improving the prognosis and prolonging survival of cancer patients. This article reviews the biomarkers of ICD and the research progress of ICD inducers to provide reference for the clinical application of ICD inducers.